Clinical trial
A Multiple Myeloma Trial in Patients With Bone Metastases
NCT00104104 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00104104 |
|---|---|
| Title | A Multiple Myeloma Trial in Patients With Bone Metastases |
| Official title | A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | zoledronic acid |
| Enrollment | 179 |
| Start date | Oct 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Feb 23, 2005 |
| Last update posted | Jun 29, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: